Lucia F Zacchi, Dinora Roche-Recinos, Cassandra L Pegg, Toan K Phung, Mark Napoli, Campbell Aitken, Vanessa Sandford, Stephen M Mahler, Yih Yean Lee, Benjamin L Schulz, Christopher B Howard
Coagulation factor IX (FIX) is a complex post-translationally modified human serum glycoprotein and high-value biopharmaceutical. The quality of recombinant FIX (rFIX), especially complete γ-carboxylation, is critical for rFIX clinical efficacy. Bioreactor operating conditions can impact rFIX production and post-translational modifications (PTMs). With the goal of optimizing rFIX production, we developed a suite of Data Independent Acquisition Mass Spectrometry (DIA-MS) proteomics methods and used these to investigate rFIX yield, γ-carboxylation, other PTMs, and host cell proteins during bioreactor culture and after purification...
March 23, 2021: Communications Biology